Amy Schulman Investor and Philanthropist

Amy Schulman is a highly accomplished investor and philanthropist, known for her impressive career in the healthcare industry. She currently serves as the CEO of Impel NeuroPharma.

Amy Schulman has made significant contributions to the field of healthcare, particularly in the area of pharmaceuticals. Her experience spans over two decades, with a strong background in finance and business development.

A unique perspective: Amy Schumer Play Volleyball

Amy Schulman's career is a testament to the power of perseverance and strategic decision-making. She began her career in litigation at Cleary Gottlieb Steen & Hamilton in 1991.

Amy's experience in law laid the foundation for her future success. She practiced law as a partner at DLA Piper before joining Pfizer.

At Pfizer, Amy held various roles, starting as general counsel and eventually moving to the business side as president of Pfizer Nutrition and president of Pfizer Consumer Healthcare. This transition demonstrates her ability to adapt and leverage her skills in new contexts.

Suggestion: Amy Matthews Sweat Equity

Amy's experience in the business side of Pfizer prepared her for her next move. She joined Polaris Partners in 2014, where she currently serves as a managing partner.

As a managing partner at Polaris Partners, Amy focuses on investing in healthcare companies and early-stage biotech start-ups. This expertise is reflected in her co-founding of the Polaris Innovation Fund in 2017.

Amy's board experience is also noteworthy. She serves as chair of the Board of Directors of Alnylam Pharmaceuticals and ByHeart, among other roles. This demonstrates her ability to lead and contribute to organizations in various capacities.

Recommended read: Amy Die

Amy Schulman is a managing partner at Polaris Partners, where she focuses on start-up investments in healthcare companies.

She serves on the boards of several companies, including Cyclerion, Dewpoint Therapeutics, and Thirty Madison.

Amy is also a director of ByHeart and has co-founded Lyndra Therapeutics, where she was the initial CEO.

She has received numerous awards, including Xconomy's 2017 Newcomer Award and Fierce Biotech's 2014 Top 15 Women in Biotech.

Amy is active in philanthropy and serves on the Boards of Action Against Hunger, Mount Sinai Hospital, and the California Institute of Technology.

Amy Schulman is a managing partner at Polaris Partners, focusing on start-up investments in healthcare companies. She has a long history of leadership roles, including serving as executive chair of SQZ Biotech and Lyndra Therapeutics.

Amy joined Polaris in 2014, taking on the role of CEO of Arsia Therapeutics, a company later acquired by Eagle Pharmaceuticals. This was after she co-founded the LS Polaris Innovation Fund in 2017.

Before joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and played a key role in the company's sale to Nestle for $11.85 billion in 2012. She then became the president of Pfizer Consumer Healthcare.

Amy Schulman has received numerous awards for her work, including Xconomy's 2017 Newcomer Award and Scientific American's 2015 Worldview 100 List.

Amy is active in philanthropic circles, serving on the Boards of Action Against Hunger and Mount Sinai Hospital, where she co-chairs the Innovations Committee.

She's also a member of the California Institute of Technology Board, which suggests her commitment to education and research.

Amy's involvement with Singapore's Health and Biomedical Sciences International Advisory Council shows her interest in global health initiatives.

Additionally, she's a member of the LifeSci NYC Advisory Council, indicating her support for biotech and life sciences in New York City.

Amy Schulman has a long history of involvement in esteemed boards and trusts. She was elected to Caltech's Board of Trustees.

As a member of various boards, Schulman has demonstrated her expertise and leadership skills. She is the chair of the board of directors of Alnylam Pharmaceuticals.

Schulman has also been a member of other notable boards, including the board of trustees at Mount Sinai Hospital, Singapore's Health and Biomedical Sciences International Advisory Council, and the LifeSci NYC Advisory Council.